Cancer Genetics Inc (NASDAQ:CGIX) has been assigned a $6.00 price objective by equities researchers at HC Wainwright in a note issued to investors on Tuesday. The firm currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price objective indicates a potential upside of 93.55% from the stock’s previous close.

CGIX has been the subject of several other reports. Zacks Investment Research downgraded Cancer Genetics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Dawson James assumed coverage on Cancer Genetics in a report on Tuesday, June 27th. They issued a “buy” rating for the company. Finally, Benchmark Co. assumed coverage on Cancer Genetics in a report on Monday, June 26th. They issued a “speculative buy” rating and a $6.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $5.56.

Shares of Cancer Genetics (CGIX) traded down 20.51% during trading on Tuesday, hitting $3.10. 775,785 shares of the company were exchanged. The firm’s 50-day moving average price is $3.82 and its 200 day moving average price is $3.45. The firm’s market capitalization is $61.26 million. Cancer Genetics has a 12 month low of $1.10 and a 12 month high of $5.30.

Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Monday, August 14th. The medical research company reported ($0.16) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). The business had revenue of $6.60 million during the quarter, compared to the consensus estimate of $7.97 million. Cancer Genetics had a negative return on equity of 165.10% and a negative net margin of 137.53%. The company’s revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.28) earnings per share. On average, equities research analysts expect that Cancer Genetics will post ($0.85) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Cancer Genetics Inc (CGIX) Given a $6.00 Price Target by HC Wainwright Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/15/cancer-genetics-inc-cgix-given-a-6-00-price-target-by-hc-wainwright-analysts.html.

In related news, Director John Pappajohn purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was purchased at an average cost of $3.75 per share, with a total value of $375,000.00. Following the completion of the acquisition, the director now directly owns 2,542,519 shares in the company, valued at $9,534,446.25. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 21.30% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of CGIX. Vanguard Group Inc. increased its stake in shares of Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares in the last quarter. Northern Trust Corp increased its stake in shares of Cancer Genetics by 61.0% in the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares in the last quarter. Thompson Davis & CO. Inc. increased its stake in shares of Cancer Genetics by 5,465.0% in the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after buying an additional 109,300 shares in the last quarter. KCG Holdings Inc. bought a new stake in shares of Cancer Genetics during the first quarter valued at $102,000. Finally, Renaissance Technologies LLC increased its stake in shares of Cancer Genetics by 44.8% in the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after buying an additional 139,200 shares in the last quarter. 12.77% of the stock is owned by hedge funds and other institutional investors.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Ratings for Cancer Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.